MedPath

OP-1 Putty for Posterolateral Fusions

Not Applicable
Completed
Conditions
Degenerative Lumbar Spondylolisthesis
Interventions
Procedure: Spinal fusion
Registration Number
NCT00677950
Lead Sponsor
Olympus Biotech Corporation
Brief Summary

The trial was designed to demonstrate the comparability of the overall success rate in the OP-1 Putty treatment group to the autograft treatment group.

Detailed Description

A controlled, open- label, blinded radiographic assessment, randomized, prospective, multicenter, multinational pivotal study in which patients with single level (L3-S1) degenerative lumbar spondylolisthesis (Grade 1 or 2) with spinal stenosis underwent decompression and spinal fusion and received OP-1 Putty or autograft. This study was a one-sided, non- inferiority trial comparing the overall success between the OP-1 Putty group and the control autograft group.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
336
Inclusion Criteria
  1. The subject has a diagnosis of Degenerative Lumbar Spondylolisthesis of Grade I or II with Spinal Stenosis demonstrated by medical history, physical examination a n d radiographic imaging.
  2. The subject is a candidate for decompression and spinal fusion with the use of autograft from the iliac crest.
  3. The subject requires one level lumbar fusion (L-3 to S-1).
  4. The subject has a preoperative Oswestry Disability Index of 30-100.
Exclusion Criteria
  1. The subject has active spinal and/or systemic infection.
  2. The subject is morbidly obese.
  3. The subject has a known sensitivity to any component of the OP-1 Putty.
  4. The subject has spinal instability measured on flexion / extension radiographs of greater than 50% translation of the vertebrae and greater than or equal to 20 degrees of angular motion.
  5. The subject uses tobacco or nicotine or is prescribed steroids such as cortisone.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1Spinal fusionOP-1 Putty
2Spinal fusionAutograft
Primary Outcome Measures
NameTimeMethod
Overall success rate at 24 months in the OP-1 Putty and the autograft groups, radiographic demonstration of spinal fusion, ODI improvement of at least 20%, no revisions, removals or supplemental fixations3, 6, 12, 24 months
Secondary Outcome Measures
NameTimeMethod
The number of anticipated and unanticipated complications/AEs that occurred within the study population, Visual Analog Scale Results for Pain Assessment, Donor Site Pain, Medication Use3, 6, 12, 24 months
© Copyright 2025. All Rights Reserved by MedPath